It is widely acknowledged that for split vaccines, potency determination is often a rate limiting step. The FDA approved gold standard potency assay for influenza hemagglutinin (HA) protein-based vaccines is single radial immunodiffusion (SRID). SRID is a time and labor intensive assay, often requiring 2-3 days to complete and a minimum of 6 hours hands-on time by well-trained analysts. Costs for SRID analysis for both pre-licensure and post-licensure testing can be more than $2 million per year for each production facility. In terms of impact on the seasonal influenza vaccine development process, perhaps even more important are the development and production delays imposed by the time required for new reference antisera. Even with reference materials in hand, the wait for results can be days for each round of clone assessment prior to moving forward in development. Overall, the result is a recognized inefficient step in the vaccine development process. If funded, this project will result in an innovative off-the shelf product that eliminates the need for referece antisera. The Flu Titer-on-Chip product will enable vaccine producers to dramatically reduce costs, standardize results, and deliver flu vaccines to market faster by streamlining quantification of hemagglutinin at all stages of vaccine development, from in-process to bulk drug substances through to tri- or quadrivalent vaccine formulations.

Public Health Relevance

InDevR will develop a product (Flu-TOC) that will enable vaccine producers to dramatically reduce costs, standardize results, and deliver flu vaccines to market faster by streamlining quantification of hemagglutinin at all stages of vaccine development, from in-process to bulk drug substances through to tri- or quadrivalent vaccine formulations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AI102318-05
Application #
9114016
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Salomon, Rachelle
Project Start
2012-05-15
Project End
2017-07-31
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
5
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Indevr, Inc.
Department
Type
DUNS #
132347787
City
Boulder
State
CO
Country
United States
Zip Code
80301
Byrne-Nash, Rose T; Miller, David F; Bueter, Katie M et al. (2018) VaxArray potency assay for rapid assessment of ""pandemic"" influenza vaccines. NPJ Vaccines 3:43
Kuck, Laura R; Saye, Stephen; Loob, Sam et al. (2017) VaxArray assessment of influenza split vaccine potency and stability. Vaccine 35:1918-1925
Kuck, Laura R; Sorensen, Michelle; Matthews, Erin et al. (2014) Titer on chip: new analytical tool for influenza vaccine potency determination. PLoS One 9:e109616